 |
Cancer biology drives personalized management ... |
|
|
|
1 - 11 |
|
|
Appropriate surgery (RO) remains the milestone ...
|
|
|
|
12 - 13 |
|
|
We can do better - Decisions on Primary Prevention |
|
|
|
14 - 15 |
|
|
Prophylactic total gastrectomy for gastric cancer |
|
|
|
16 - 18 |
|
|
Preventing CDH1 Mutation Carriers |
|
|
|
19 - 21 |
|
|
Prevention of hereditary cancer syndromes |
|
|
|
22 - 24 |
|
|
Risk-reducing surgery in the prevention of hereditary cancer syndromes |
|
|
|
25 - 27 |
|
|
Genomewide Association Studies – Strengthens and Challenges in the Clinic ... |
|
|
|
28 - 31 |
10.2122/gbc.2006.0059 |
|
The importance of surgical margin control in breast-conserving therapy...
|
|
|
|
32 - 33 |
10.2122/gbc.2006.0060 |
|
Reducing local recurrence after Breast-conserving surgery for breast cancer |
|
|
|
34 - 36 |
10.2122/gbc.2007.0061 |
|
Increased risk of local recurrence after breast-conserving therapy in young patients |
|
|
|
37 - 38 |
10.2122/gbc.2007.0062 |
|
Gene signatures and breast cancer network biology: Ready to the clinic? |
|
|
|
39 - 40 |
10.2122/gbc.2007.0063 |
|
Outcomes of breast cancer patients with and without BRCA1/2 mutations |
|
|
|
41 - 43 |
10.2122/gbc.2007.0064 |
|
Targeting Gastric Cancer: Inhibiting signal transduction pathways |
|
|
|
44 - 55 |
10.2122/gbc.2007.0065 |
|
Current Treatment of Gastric Cancer: More Complicated than Ever |
|
|
|
56 - 59 |
10.2122/gbc.2006.0066 |
|
Asssessment of Laparoscopic Approach in Gastric Cancer
|
|
|
|
59 - 61 |
10.2122/gbc.2006.0067 |
|
Advances in Laparoscopic Gastrectomy |
|
|
|
62 - 65 |
10.2122/gbc.2007.0068 |
|
Laparoscopic Gastrectomy: Advances Enable Wide Clinical Application |
|
|
|
66 - 69 |
10.2122/gbc.2007.0069 |
|
Prognosis of BRCA and non BRCA mutation carriers |
|
|
|
70 - 72 |
10.2122/gbc.2007.0070 |
|
Choosing Preventive Intervention in BRCA mutation Carriers |
|
|
|
73 - 75 |
10.2122/gbc.2007.0071 |
|
A Study of Tissue Bcl-2 Expression and Its Serum Levels in Breast Cancer Patients |
|
|
|
76 - 83 |
10.2122/gbc.2007.0072 |
|
BREAKTHROUGH
HUMAN GENOME GENETIC VARIATION AND CLINIC |
|
|
|
1 - 11 |
|
|
Incorporating Genetic Testing for Guided Prevention of Contralateral Breast Cancer
|
|
|
|
12 - 13 |
|
|
Minimal residual disease in breast cancer: Can it be used as prognostic marker? |
|
|
|
14 - 15 |
|
|
Preventing Contralateral Breast Cancer |
|
|
|
16 - 18 |
|
|
Cancer origin and Metastasis - Does Local Control Affect Overall Survival for Solid Cancer? |
|
|
|
19 - 21 |
|
|
Endoscopic Mucosal Resection - Is safe and Effective for Early Diffuse-type Gastric Cancer? |
|
|
|
22 - 24 |
|
|
Benefits and harms in avoiding Axilla Lymphadenectomy in Breast Cancer |
|
|
|
25 - 27 |
|
|
Targeting HER2 Breast Cancer With Trastuzumab, Lapatinib and Other Novel Agents: Clinical Success and Resistance |
|
|
|
28 - 31 |
10.2122/gbc.2008.0080 |
|
Prognostic Value of Epidermal Growth Factor Receptor in Breast Cancer: An Indian Experience |
|
|
|
56 - 64 |
10.2122/gbc.2008.0082 |
|
Tailoring surgery for breast cancer – Genetic Testing-based current practice and promises with Genomewide Association studies |
|
|
|
45 - 52 |
10.2122/gbc.2008.0083 |
|
Bevacizumab for metastatic breast cancer – Promise and Concerns |
|
|
|
53 - 55 |
10.2122/gbc.2008.0084 |
|
Structural genomic variation: Human Copy Number Variation Promise Towards Personalized Medicine |
|
|
|
65 - 68 |
10.2122/gbc.2008.0085 |
|
Da Vinci System for Robotic Rectal Cancer Surgery |
|
|
|
69 - 70 |
10.2122/gbc.2008.0086 |
|
VEGF and EGFR Antagonists for Gastric Cancer |
|
|
|
71 - 73 |
10.2122/gbc.2008.0087 |
|
Treatment of Localized Gastric Adenocarcinoma |
|
|
|
74 - 79 |
|
|
Personal genomics and practical personalized medicine – Overcoming challenges? |
|
|
|
80 - 82 |
10.2122/gbc.2008.0088 |
|
Genetics and personal genome towards personalized breast cancer local control. |
|
|
|
83 - 85 |
10.2122/gbc.2008.0089 |
|
High-volume surgeons improve esophagus cancer oncological outcomes. |
|
|
|
86 - 88 |
10.2122/gbc.2008.0090 |
|
Genetic variation –SNPs/CNVs- and potential anticancer applications. |
|
|
|
89 - 91 |
10.2122/gbc.2008.0091 |
|
Laparoscopic colectomy for cancer. |
|
|
|
92 - 95 |
10.2122/gbc.2008.0092 |
|
Treatment of Localized Gastric Adenocarcinoma |
|
|
|
96 - 109 |
10.2122/gbc.2008.0093 |
|
Epidermal Growth Factor Receptor perspectives for Breast Cancer. |
|
|
|
110 - 112 |
10.2122/gbc.2008.0094 |
|
D2 vs. D4 lymphadenectomy for gastric cancer. |
|
|
|
113 - 117 |
10.2122/gbc.2008.0095 |
|
DNA variation-based research including GWA studies may yield in understanding “genotype-phenotype mapping” through innovative causative network brilliant models |
|
|
|
1 - 2 |
|
|
Solid cancer is a highly complex-heterogeneous disease. |
|
|
|
3 - 5 |
|
|
H. pylori-diet and genetic factors interactions: Quantitative genetics gastric cancer targeted screening and prevention |
|
|
|
6 - 12 |
|
|
Robotic Surgery: New Era in the Treatment of Solid Cancer. |
|
|
|
13 - 18 |
|
|
KRAS AND SIGNALING NETWORK: NEW THINK NEW DRUGS ERA |
|
|
|
19 - 24 |
|
|
Laparoscopic Gastrectomy: HIGH-VOLUME SURGEONS |
|
|
|
25 - 28 |
|
| |
Personal Genetics and impact on breast surgeon |
|
|
|
29 - 31 |
|
|
Laparoscopic Gastrectomy: Evidence for improved QOL |
|
|
|
32 - 34 |
|
|
Targeted Agents and Biomarkers Promises and Pitfalls: Personal Genomics, Bioinformatics and Systems Biology Drive Novel Drugs Discovery and Markers for Personalized Cancer Biomedicine. |
|
|
|
|
|
|
Personalized Molecular cancer-targeted therapy |
|
|
|
39 - 46 |
|
|
Bevacizumab: Limitations for Breast Cancer Treatment |
|
|
|
29 - 30 |
|
|
Impact of genetics and genomics in breast cancer surgery |
|
|
|
36 - 38 |
|
|
New era in cancer surgical treatment |
|
|
|
31 - 35 |
|
|
Rectal cancer resection |
|
|
|
47 - 49 |
|
|
Laparoscopic Colectomy for Colon Cancer |
|
|
|
50 - 52 |
|
|
Personal genomics for early Breast cancer
How targeted therapy, genetics and personal genomics may prevent local failures and improve Local outcomes. |
|
|
|
53 - 69 |
|
|
Systems medicine for a next-generation of biomarkers and drugs: Changing poor cancer outcomes. |
|
|
|
1 - 23 |
|
|
Why Gastric and Breast Cancer Journal ? CDH1 and HER2 |
|
|
|
24 - 26 |
|
|
Nipple-Sparing Mastectomy |
|
|
|
27 - 28 |
|
|
Open or laparoscopic colorectal cancer resection: standardization and lymph nodes retried |
|
|
|
34 - 35 |
|
|
Low anterior rectal resection for rectal cancer: Why laparoscopic or robotic surgery may improve outcomes? |
|
|
|
29 - 30 |
|
|
Laparoscopic D2 gastrectomy: A new horizon even in the West |
|
|
|
31 - 33 |
|
|
Very early (T1a,bN0) breast cancer: HER2 and algorithmic approach to predict and treat patients at high recurrence risk |
|
|
|
36 - 44 |
|
| |
The new era of systems medicine and cancer networks |
|
|
|
45 - 50 |
|
| |
Why Gastric and Breast Cancer Journal ? CDH1 and HER2 |
|
|
|
51 - 54 |
|
| |
Challenges for personalized medicine: A 2020 vision |
|
|
|
55 - 59 |
|
| |
Advances in laparoscopic gastrectomy for early and advanced resectable gastric cancer |
|
|
|
60 - 64 |
|
| |
Endoscopic submucosal dissection for gastric tube cancer after esophagectomy |
|
|
|
65 - 67 |
|
| |
Challenges and expectations for novel biologics discovery in HER2-negative breast cancer |
|
|
|
68 - 69 |
|
|
Genetic geographical ancestry and breast cancer: Exploring potential phenotypic clinical differences in patients from Africa and Europe |
|
|
|
70 - 72 |
10.2122/gbc.2010.0125 |
| |
Decision-making treatment for early breast cancer and future perspectives |
|
|
|
73 - 82 |
|
|
Reversing Cancer and Ageing: Multiple Personal Genomes, Life Complexity and Myriad Clinical Challenges |
|
|
|
83 - 87 |
10.2122/gbc.2010.0127 |
|
Cetuximab, panitumumab and bevacizumab resistance in colorectal cancer: Are molecular networks the solution? |
|
|
|
88 - 94 |
10.2122/gbc.2010.0129 |
|
Comparative-effectiveness research and personalized medicine: Trends and debate |
|
|
|
95 - 101 |
10.2122/gbc.2010.0130 |
|
Evidence-based laparoscopic surgery for low rectal cancer |
|
|
|
102-105 |
10.2122/gbc.2010.0131 |
|
Trastuzumab for small HER2-positive breast cancer? Uncertainty and new research directions |
|
|
|
106-109 |
10.2122/gbc.2010.0132 |
|
Intellectual innovation and new technology in surgical oncology |
|
|
|
110-112 |
10.2122/gbc.2010.0133 |
|
Western challenges with esophagectomy and follow-up |
|
|
|
113-115 |
10.2122/gbc.2010.0134 |
|
Standardizing colorectal cancer treatment |
|
|
|
116-118 |
10.2122/gbc.2010.0135 |
|
Selection and identification of DNA aptamers to gastric cancer cell SGC-7901 |
|
|
|
119-126 |
10.2122/gbc.2010.0128 |
